Prevención de las enfermedades infecciosas. Actualización en vacunas, 2020

Chavarri, Germán Schwarz; Hernández, Coro Sánchez; Millán, Nemesio Moreno; Agustí, María Luisa Morató; Martín, Susana Martín; Miranda, Ana Pilar Javierre; Pérez, María Isabel Gutiérrez; Marco, José Javier Gómez; García-Iglesias, Cristina; Herce, Pablo Aldaz; Papps, Grupo de Prevención de Enfermedades Infecciosas del

doi:10.1016/j.aprim.2020.08.001

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tetanus is a disease that can be totally controlled, being preventable by vaccination, but it is not eradicable, since Clostridium tetani is a widespread microorganism found in the environment ( 2 ). Immunization is highly effective, affording long-term protection and is recommended for the general population, though for immunity to be maintained, a booster dose must be administered after completion of the primary vaccination ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

“…In the case of injuries, the need to administer active immunization (tetanus toxoid), whether alone or in tandem with passive immunization (anti-tetanus immunoglobulin), depends on the type of wound involved, the probability of its becoming contaminated with tetanus bacilli, and the patient's vaccine record ( 3 ). Currently, administration of the combined tetanus-diphtheria (Td) vaccine (presentation for adults) by intramuscular route is recommended ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and safety of tetanus vaccine administration by intramuscular vs. subcutaneous route in anticoagulated patients: Randomized clinical trial in primary care

Lago-Deibe

Valladares-Cabaleiro²,

Fernández-Domínguez

et al. 2022

Front. Med.

View full text Add to dashboard Cite

DesignProspective, double-blind clinical trial comparing tetanus-diphtheria vaccine administration routes, intramuscular (IM) vs. subcutaneous (SC) injection, in patients with oral anticoagulants. ISRCTN69942081.Study populationPatients treated with oral anticoagulants, 15 health centers, Vigo (Spain). Sample size, 117 in each group.Outcome variablesSafety analysis: systemic reactions and, at the vaccine administration site, erythematic, swelling, hematoma, granuloma, pain.Effectiveness analysis: differences in tetanus toxoid antibody titers.Independent variables: route, sex, age, baseline serology, number of doses administered.AnalysisFollowing the CONSORT guidelines, we performed an intention-to-treat analysis. We conducted a descriptive study of the variables included in both groups (117 in each group) and a bivariate analysis. Fewer than 5% of missing values. Imputation in baseline and final serology with the median was performed. Lost values were assumed to be values missing at random. We conducted a descriptive study of the variables and compared routes. For safety, multivariate logistic regression was applied, with each safety criterion as outcome and the independent variables. Odds ratios (ORs) were calculated. For effectiveness, a generalized additive mixed model, with the difference between final and initial antibody titers as outcome. Due to the bimodal distribution of the outcome, the normal mixture fitting with gamlssMX was used. All statistical analyses were performed with the gamlss.mx and texreg packages of the R free software environment.ResultsA previously published protocol was used across the 6-year study period. The breakdown by sex and route showed: 102 women and 132 men; and 117 IM and 117 SC, with one dose administered in over 80% of participants. There were no differences between groups in any independent variable. The second and third doses administered were not analyzed, due to the low number of cases. In terms of safety, there were no severe general reactions. Locally, significant adjusted differences were observed: in pain, by sex (male, OR: 0.39) and route (SC, OR: 0.55); in erythema, by sex (male, OR: 0.34) and route (SC, OR: 5.21); and in swelling, by sex (male, OR: 0.37) and route (SC, OR: 2.75). In terms of effectiveness, the model selected was the one adjusted for baseline serology.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of tetanus vaccine administration by intramuscular vs. subcutaneous route in anticoagulated patients: Randomized clinical trial in primary care

Lago-Deibe

Valladares-Cabaleiro²,

Fernández-Domínguez

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…The Spanish Healthcare System also recommends the vaccination of other at-risk population groups, either due to previous pathologies such as immunosuppression, asple-nia, and/or transplanted patients [5,6], or due to a high exposure risk, such as essential healthcare workers [7].…”

Section: Introductionmentioning

confidence: 99%

Fendrix® Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B® Vaccination

et al. 2021

View full text Add to dashboard Cite

Hepatitis B (HBV) is a pathogen virus with transmission mechanisms that include contact with the infected blood or bodily fluids of the infected organism. Nowadays, healthcare workers are one of the most exposed groups to HBV. Conventionally, completing a vaccine series dosage with Engerix B® lowers this risk by providing workers with immunity to the virus. However, through the years, we have encountered nonresponsive health personnel to the Engerix B® vaccine; hence, the Occupational Health Service of Poniente Hospital studied the Fendrix® adjuvanted vaccine as an alternative vaccine to develop immunological responses in healthcare workers who do not respond to vaccination with Engerix B®. In our study, we employed a vaccination schedule with the Fendrix® vaccine, performing serology tests on the cases after the application of each dose. The results obtained showed humoral immunity in 92.3% of the cases, with a remarkable increase in antibody titer after the first doses. These encouraging results support the future inclusion of this vaccine as one possible alternative for the immunization to HBV for healthcare workers nonresponsive to Engerix B®.

show abstract

“…This has led to a rethinking of vaccine policies around the world. In Spain, for example, the vaccination schedule, previously divided into paediatric and adult, has been updated to a single lifelong schedule [165,166]. In the case of the influenza vaccination recommendation in our country, it focus on groups at high risk of suffering complications in the event of the disease, as well as people in contact with them [167].…”

Section: Preferential Vaccine Administration Groupsmentioning

confidence: 99%

Humoral immune response after seasonal influenza vaccination

Sánchez de Prada

View full text Add to dashboard Cite

Se me hace di4cil creer que haya llegado este momento. Querría empezar mencionando a mis directores, los Dr. José María Eiros, Dr. Iván Sanz Muñoz y la Dra. Teresa Aydillo. Agradezco profundamente vuestra paciencia, confianza y apoyo a lo largo de este camino sin los cuales no habría podido finalizar. Me habéis transmiOdo vuestra sabiduría, ganas e ilusión.Gracias a Teresa de nuevo y al Dr. Adolfo García-Sastre por haberme dado la oportunidad de formarme con ellos en el Mount Sinai de Nueva York y descubrirme un mundo apasionante. Gracias también a todo el laboratorio por haberme acogido como lo hicieron y haberme hecho senOr como en casa durante esos tres meses allí.Gracias a todos mis compañeros del laboratorio de Microbiología del Hospital

show abstract

Prevención de las enfermedades infecciosas. Actualización en vacunas, 2020

Cited by 9 publications

References 0 publications

Effectiveness and safety of tetanus vaccine administration by intramuscular vs. subcutaneous route in anticoagulated patients: Randomized clinical trial in primary care

Effectiveness and safety of tetanus vaccine administration by intramuscular vs. subcutaneous route in anticoagulated patients: Randomized clinical trial in primary care

Fendrix® Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B® Vaccination

Humoral immune response after seasonal influenza vaccination

Contact Info

Product

Resources

About